Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
St. Clare Hospital
mi
from
Lakewood, WA
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
St. Clare Hospital
mi
from
Lakewood, WA
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Capital Medical Center
mi
from
Olympia, WA
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Capital Medical Center
mi
from
Olympia, WA
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Providence St. Peter Hospital Regional Cancer Center
mi
from
Olympia, WA
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Providence St. Peter Hospital Regional Cancer Center
mi
from
Olympia, WA
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Olympic Medical Center
mi
from
Port Angeles, WA
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Olympic Medical Center
mi
from
Port Angeles, WA
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Good Samaritan Cancer Center
mi
from
Puyallup, WA
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Good Samaritan Cancer Center
mi
from
Puyallup, WA
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Valley Medical Center
mi
from
Renton, WA
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Valley Medical Center
mi
from
Renton, WA
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
CCOP - Virginia Mason Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
CCOP - Northwest
mi
from
Tacoma, WA
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
CCOP - Northwest
mi
from
Tacoma, WA
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
St. Joseph Medical Center at Franciscan Health System
mi
from
Tacoma, WA
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
St. Joseph Medical Center at Franciscan Health System
mi
from
Tacoma, WA
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Allenmore Hospital
mi
from
Tacoma, WA
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Allenmore Hospital
mi
from
Tacoma, WA
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Camden-Clark Memorial Hospital
mi
from
Parkersburg, WV
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Camden-Clark Memorial Hospital
mi
from
Parkersburg, WV
Click here to add this to my saved trials
Sunitinib to Treat Recurrent Brain Cancer
A Phase II Trial of Sunitinib in the Treatment of Recurrent Malignant Gliomas
Status: Enrolling
Updated:  9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Sunitinib to Treat Recurrent Brain Cancer
A Phase II Trial of Sunitinib in the Treatment of Recurrent Malignant Gliomas
Status: Enrolling
Updated: 9/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma
Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma)
Status: Enrolling
Updated:  9/30/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma
Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma)
Status: Enrolling
Updated: 9/30/2015
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma
Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma)
Status: Enrolling
Updated:  9/30/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma
Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma)
Status: Enrolling
Updated: 9/30/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma
Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma)
Status: Enrolling
Updated:  9/30/2015
Lucile Packard Children's Hospital at Stanford University Medical Center
mi
from
Palo Alto, CA
Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma
Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma)
Status: Enrolling
Updated: 9/30/2015
Lucile Packard Children's Hospital at Stanford University Medical Center
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Status: Enrolling
Updated:  9/30/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Status: Enrolling
Updated: 9/30/2015
Indiana University Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Status: Enrolling
Updated:  9/30/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Status: Enrolling
Updated: 9/30/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Status: Enrolling
Updated:  9/30/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy
Status: Enrolling
Updated: 9/30/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Malignant Glioma
Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas
Status: Enrolling
Updated:  9/30/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Vaccine Therapy in Treating Patients With Malignant Glioma
Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas
Status: Enrolling
Updated: 9/30/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma.
Status: Enrolling
Updated:  10/1/2015
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma.
Status: Enrolling
Updated: 10/1/2015
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma.
Status: Enrolling
Updated:  10/1/2015
Helen DeVos Children's Hospital
mi
from
Grand Rapids, MI
Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma.
Status: Enrolling
Updated: 10/1/2015
Helen DeVos Children's Hospital
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
Prospective Study on the Short-Term Adverse Effects From Gamma Knife Radiosurgery
Status: Enrolling
Updated:  10/1/2015
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
Prospective Study on the Short-Term Adverse Effects From Gamma Knife Radiosurgery
Status: Enrolling
Updated: 10/1/2015
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Malignant Glioma
Phase I Study of Glioma-Associated Antigen (GAA) Peptide-pulsed Dendritic Cell Vaccination in Malignant Glioma Patients
Status: Enrolling
Updated:  10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Vaccine Therapy in Treating Patients With Malignant Glioma
Phase I Study of Glioma-Associated Antigen (GAA) Peptide-pulsed Dendritic Cell Vaccination in Malignant Glioma Patients
Status: Enrolling
Updated: 10/1/2015
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
Status: Enrolling
Updated:  10/2/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
Status: Enrolling
Updated: 10/2/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Proton Radiation Therapy for Pituitary Adenoma
Clinical Outcomes Study of Proton Radiation Therapy for Pituitary Adenoma
Status: Enrolling
Updated:  10/2/2015
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Proton Radiation Therapy for Pituitary Adenoma
Clinical Outcomes Study of Proton Radiation Therapy for Pituitary Adenoma
Status: Enrolling
Updated: 10/2/2015
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study
Status: Enrolling
Updated:  10/5/2015
Overlook Hospital
mi
from
Summit, NJ
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study
Status: Enrolling
Updated: 10/5/2015
Overlook Hospital
mi
from
Summit, NJ
Click here to add this to my saved trials
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study
Status: Enrolling
Updated:  10/5/2015
New York University Clinical Cancer Center
mi
from
New York, NY
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study
Status: Enrolling
Updated: 10/5/2015
New York University Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
A Multicenter, Two Stage, Phase II Study, Evaluating the Efficacy of Oral BEZ235 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Status: Enrolling
Updated:  10/5/2015
Indiana University SC
mi
from
Indianapolis, IN
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
A Multicenter, Two Stage, Phase II Study, Evaluating the Efficacy of Oral BEZ235 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Status: Enrolling
Updated: 10/5/2015
Indiana University SC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
A Multicenter, Two Stage, Phase II Study, Evaluating the Efficacy of Oral BEZ235 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Status: Enrolling
Updated:  10/5/2015
Montefiore Medical Center SC-2
mi
from
Bronx, NY
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
A Multicenter, Two Stage, Phase II Study, Evaluating the Efficacy of Oral BEZ235 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Status: Enrolling
Updated: 10/5/2015
Montefiore Medical Center SC-2
mi
from
Bronx, NY
Click here to add this to my saved trials
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
A Multicenter, Two Stage, Phase II Study, Evaluating the Efficacy of Oral BEZ235 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Status: Enrolling
Updated:  10/5/2015
Ohio State Comprehensive Cancer Center/James Cancer Hospital SC
mi
from
Columbus, OH
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
A Multicenter, Two Stage, Phase II Study, Evaluating the Efficacy of Oral BEZ235 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Status: Enrolling
Updated: 10/5/2015
Ohio State Comprehensive Cancer Center/James Cancer Hospital SC
mi
from
Columbus, OH
Click here to add this to my saved trials
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
A Multicenter, Two Stage, Phase II Study, Evaluating the Efficacy of Oral BEZ235 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Status: Enrolling
Updated:  10/5/2015
Dana Farber Cancer Institute GastrointestionalCancer Clinic
mi
from
Boston, MA
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
A Multicenter, Two Stage, Phase II Study, Evaluating the Efficacy of Oral BEZ235 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Status: Enrolling
Updated: 10/5/2015
Dana Farber Cancer Institute GastrointestionalCancer Clinic
mi
from
Boston, MA
Click here to add this to my saved trials
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
A Multicenter, Two Stage, Phase II Study, Evaluating the Efficacy of Oral BEZ235 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Status: Enrolling
Updated:  10/5/2015
Novartis Investigative Site
mi
from
Wien,
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
A Multicenter, Two Stage, Phase II Study, Evaluating the Efficacy of Oral BEZ235 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
Status: Enrolling
Updated: 10/5/2015
Novartis Investigative Site
mi
from
Wien,
Click here to add this to my saved trials
TRC105 for Recurrent Glioblastoma
A Phase 2 Study of TRC105 in Patients With Recurrent Glioblastoma (GBM)
Status: Enrolling
Updated:  10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
TRC105 for Recurrent Glioblastoma
A Phase 2 Study of TRC105 in Patients With Recurrent Glioblastoma (GBM)
Status: Enrolling
Updated: 10/6/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Investigational Drug Service
mi
from
Atlanta, GA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Investigational Drug Service
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
The Emory Clinic
mi
from
Atlanta, GA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Loyola University Medical Center
mi
from
Maywood, IL
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Siteman Cancer Center-West County
mi
from
Creve Couer, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Siteman Cancer Center-West County
mi
from
Creve Couer, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Barnes Jewish Hospital
mi
from
St. Louis, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Barnes Jewish Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Washington University School of Medicine, Siteman Cancer Center
mi
from
St. Louis, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Washington University School of Medicine, Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Siteman Cancer Center
mi
from
St. Peters, MO
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Siteman Cancer Center
mi
from
St. Peters, MO
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Comprehensive Cancer Center of Nevada
mi
from
Las Vegas, NV
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Comprehensive Cancer Center of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Northwest Cancer Specialists, Pc
mi
from
Portland, OR
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fort Worth, TX
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fortworth, TX
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
US Oncology Research and Clinical Pharmacy (Drug Shipment Only)
mi
from
Fortworth, TX
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
The Strelitz Diabetes Institute of Eastern Virginia Medical School
mi
from
Norfolk, VA
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
The Strelitz Diabetes Institute of Eastern Virginia Medical School
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated:  10/7/2015
Clinica Viedma
mi
from
Viedma,
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
An Open-label Sunitinib Malate (su011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment
Status: Enrolling
Updated: 10/7/2015
Clinica Viedma
mi
from
Viedma,
Click here to add this to my saved trials
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Phase I Dose Escalation of Gleevec in Combination With PTK787/ZK 222584 (PTK/ZK) Plus Hydroxyurea
Status: Enrolling
Updated:  10/11/2015
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Phase I Dose Escalation of Gleevec in Combination With PTK787/ZK 222584 (PTK/ZK) Plus Hydroxyurea
Status: Enrolling
Updated: 10/11/2015
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials